Pharmaceutical manufacturers face a revenue contraction of 62% from their top-selling assets by 2030.1 Blockbuster drugs representing $236 billion in […]
Drug Reformulation Strategy: Buy Seven Years of Exclusivity for $20 Million Read Post »
How to use market automation and drug patent intelligence to build pipeline before generic entry kills your best customers’ budgets
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers Read Post »
Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This
Forecasting Generic Entry: Combining FDA Orange Book with Paragraph IV Notice Letters Read Post »
The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been
Branded Generics: The $400 Billion Business That Big Pharma Can’t Ignore In the summer of 2022, a pharmacist in Lagos
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets Read Post »
The companies winning enterprise contracts in biopharma data intelligence aren’t selling better patent databases. They’re selling a connected answer to
Every major drug patent expiration triggers a predictable downstream event: the originator company races to defend margin, and a dozen
The LOE Wave Nobody in Equipment Sales Is Talking About Between 2024 and 2029, roughly $130 billion worth of branded
The Revenue Cliff Is Real, and So Is Your Window Every year, billions of dollars in branded pharmaceutical revenue evaporate
Get fresh news and insights, drug patent expirations & more…
